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In Mediterranean woodlands of Iberia, the Eurasian wild boar (Sus scrofa) is considered 
as the main wild reservoir of the Mycobacterium tuberculosis complex (MTC), and a 
key risk for cattle tuberculosis (TB) breakdowns. In this context, wild boar vaccination 
might represent a valuable tool for TB control. We tested two vaccines in natural and 
managed sites: heat-inactivated M. bovis (IV) and BCG,	each	one	deployed	during	
four	consecutive	summers	using	selective	piglet	feeders. Piglets from natural sites 
had lower bait uptake rates (50 to 74%) than those from managed sites (89 to 92%). 
Piglet TB lesion prevalence increased by 6% in the Control and Managed BCG sites, 
and decreased 36% in the Natural IV site. In the Natural BCG site the control year 
sample size was too low for comparisons. In the managed IV site, piglet TBCL 
prevalence remained 0% throughout the study period. At the population scale, TB lesion 
prevalence increased in the Control sites (5.6%), while a significant decline occurred in 
the Managed IV site (34.4%). No changes were recorded in the remaining sites. We 
conclude that IV can become part of integrated TB control schemes, although its 
performance is context dependent and requires tailored field protocols.  
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INTRODUCTION 
Vaccination is one of the most effective tools to prevent, control and eradicate 
infectious diseases (Rappuoli et al. 2001, McVey et al. 2010). In free-ranging wildlife, 
the technical and logistical difficulties and the cost of vaccination limit its application to 
diseases that have significant public health, economical or conservation impact (Cross 
et al. 2007). The turning point of wildlife vaccination was the control of fox (Vulpes 
vulpes) rabies in Europe (Freuling et al. 2013).  
This success prompted the investigation of field vaccination strategies to control other 
relevant diseases in wildlife, including animal tuberculosis (TB). This chronic infection 
is caused by Mycobacterium bovis (M. bovis), Mycobacterium caprae (M. caprae) and 
other members of the Mycobacterium tuberculosis complex (MTC). It is a zoonosis, 
although nowadays the number of human cases is low in industrialized countries 
(Langer and LoBue 2014). Hence, the impact of animal TB is mainly socio-economical 
and derives from the eradication campaign costs, associated movement restrictions, and 
indirect losses to the livestock industry (Zingsstag et al. 2006), as well as regionally to 
the hunting industry (Barasona et al. 2016). Moreover, animal TB causes conservation 
concerns, e.g. in the endangered Iberian lynx, Lynx pardinus (López et al. 2014). 
Most TB-control efforts focus on cattle as the main target host (Reviriego Gordejo and 
Vermeersch 2006). However, TB is a paradigmatic example of multi-host infection and 
its eradication remains unlikely without targeting all relevant hosts (Gortázar et al. 
2015). In Mediterranean woodland habitats of the Iberian Peninsula, the MTC host 
network is complex and includes several relevant domestic and wild host species 
(Aranaz et al. 2004, Gortazar and Boadella 2014). In this region, the native Eurasian 
wild boar (Sus scrofa) is considered as the main wild reservoir for MTC (Naranjo et al. 
2008). This suid is also regarded as a key risk for cattle TB breakdowns (La Hue et al. 
2016, Hardstaff et al. 2014), mostly through indirect contacts (Kukielka et al. 2013, 
Cowie et al. 2015).  
In consequence, wild boar are becoming an additional target for TB control. There is 
evidence suggesting that interventions on wild boar such as biosafety measures reducing 
wildlife– cattle contacts (Barasona et al. 2013), or culling (Boadella et al. 2012), 
manage to reduce TB prevalence in sympatric ruminants such as cattle and red deer 
(Cervus elaphus). In this context, wild boar vaccination might represent a valuable 
additional tool for TB control in Mediterranean Iberia.  
Proof of principle of TB disease reduction by vaccination with the life attenuated BCG 
has been demonstrated for several wild reservoirs in controlled experiments (Buddle et 
al. 2006, Lesellier et al. 2006, Nol et al. 2008). Further field experiments have been 
conducted in brush-tailed possums (Trichosurus vulpecula; Corner et al. 2002, 
Tompkins et al. 2009 and Nugent et al. 2016) and Eurasian badgers (Meles meles; 
Chambers et al. 2011 and Gormley et al. 2017) with promising results regarding 
protection (Table 1). 
Two vaccine candidates administered by the oral route have been tested in laboratory 
trials in the wild boar model: BCG (Ballesteros et al. 2009a, Garrido et al. 2011, 
Gortázar et al. 2014) and heat-inactivated M. bovis (IV) (Garrido et al. 2011, Beltrán-
Beck et al. 2014a). Both vaccines decrease disease severity, reducing lesion and culture 
scores, when compared to unvaccinated controls. Vaccine safety and species-specific 
delivery at field has been assessed in additional trials (Beltrán-Beck et al. 2014b).  
Both vaccines are prophylactic and non-sterilizing. Thus, their protective effect is 
expected to reduce the severity of the disease and subsequent transmission, rather than 
preventing infection. The vaccination target are 2-6 month old wild boar since they have 
a higher chance of being uninfected (Ballesteros et al. 2009b). The vaccines are 
formulated for oral delivery, as oral administration via baits is the most practical means 
for wildlife vaccination at large scales (Cross et al. 2007). This coupled with 
complementary tools such as species-specific baits (Ballesteros et al. 2009c) marked 
with chemical compounds (Ballesteros et al. 2011) and selective baiting stations 
(Ballesteros et al. 2009b) enables a targeted vaccine delivery and accurate bait uptake 
assessment.  
An injectable version of the IV vaccine successfully reduced TB lesion prevalence in a 
wild boar farm (66% reduction; Díez-Delgado et al. 2016). However, extensive field 
trials are needed to assess vaccine performance under realistic oral delivery conditions 
in free ranging populations. Therefore, in 2012 a large-scale (ca. 460 km2), four-year 
wild boar oral vaccination experiment was implemented in a high prevalence area of 
Montes de Toledo, Spain.  
Our aims were, first, assessing vaccine impact measured as changes in TB prevalence at 
the wild boar population scale based on pathology and culture; second, assessing a key 
operational aspect of oral vaccination (bait uptake) under field conditions; and third, 
modelling field vaccination in order to gather additional insights regarding (i) the 
influence of different levels of vaccination success on disease prevalence and the 
influence of continued vaccination (25 years) and eventual cessation on (ii) population 
density and on (iii) disease prevalence in two scenarios representative of the situations 
encountered at field. 
 
MATERIALS AND METHODS 
 
Animal use 
The experiment was conducted under a research license (828493/2011) issued by D.G. 
Agricultura y Ganadería, Junta de Castilla - La Mancha. Post-mortem inspection and 
sampling was performed on hunter-harvested wild boar. No animal was culled because 
of the experiment.  
 
Study area 
The study was conducted in Montes de Toledo, a mountain chain located in Central 
Spain (39 º 25 'to 39 ° 16'N, 4 ° 05' to 4 ° 23 'W). This region has a Mediterranean wood 
and scrubland habitat dominated by evergreen oaks (Quercus sp). The climate is typical 
Mediterranean, with mild to cold winters, hot summers and rainfall mostly limited to 
spring and autumn.  
The study area is composed by an array of private owned hunting estates, communal 
lands and protected natural areas representing a gradient of wildlife management. Land 
use changes have favoured the upsurge of a commercial hunting industry economically 
relevant for the area, which main big game species are red deer and wild boar, leading 
to high ungulate densities (Vicente et al. 2013). 
In this TB endemic area wild boar TB-compatible lesion (TBCL) prevalence ranges 
from 52% to 70% and shows an increasing trend in time (Vicente et al. 2013). In 
contrast, lower (12%) and relatively stable TCBL prevalence has been described for red 
deer (Vicente et al. 2013).  
A total of 19 sites were selected for TB monitoring. Out of them, 2 private owned 
hunting estates and a natural park were devoted to vaccination (96 km2) and the 
remaining sites were used as control (n=15, ca. 360 km2).  
BCG was deployed in one of the private owned estates (Managed BCG) and IV in the 
other one (Managed IV). The natural park was divided in two areas separated by a 
topographical barrier (a flat area of 4 km with less vegetation, crossed by the main road 
that separates the north and south mountain chains); BCG was deployed in the north 
area (Natural BCG) while IV was deployed in the south (Natural IV; Figure 1). Further 




The live attenuated BCG vaccine derives from M. bovis Danish (CCUG strain 27863) 
and was prepared as described elsewhere (Ballesteros et al. 2009a, Garrido et al. 2011, 
Gortázar et al. 2014). Vaccine doses of 0.15 ml of a suspension containing 5.2 to 7.6 
x105 c.f.u. were placed into sterile airtight polypropylene 0.2 ml vials (VWR®, Radnor, 
Pensilvania, USA). BCG was freshly prepared for each cycle and stored at 4ºC until 
deployment in the field (24 to 72 hours). 
The IV vaccine derives from a heat-inactivated field isolate obtained from a naturally 
infected wild boar (Neiker1403, spoligotype SB0339) and is prepared as described in 
Garrido et al. (2011). Each IV vial contains a dose of approximately 6x107c.f.u. in 0.2 




BCG and IV vaccine vials are deployed in baits specific for wild boar piglets 
(Ballesteros et al. 2009c). These baits have demonstrated their stability, safety 
and effectiveness in reaching the target species and age class in the field 
(Ballesteros et al. 2011). A chemical marker, iophenoxic acid (IPA; PR 
EuroCHEM Ltd., Cork, Ireland), is added to the baits (as described in 
Ballesteros et al. 2011) to determine the proportion of wild boar piglets 
consuming baits (bait uptake). Two IPA derivatives, each one associated to a 
vaccine type, were employed. Propil-IPA was associated with BCG baits and 
ethyl-IPA to IV baits.  
(ii) Selective piglet feeders and spatial distribution 
Baits were placed at selective piglet feeders (Ballesteros et al. 2009a). Treatment 
surfaces were divided into a 2 km2 grid by means of GIS analysis (QGIS version 
1.8.0 Lisboa). Piglet feeders were distributed by couples per grid. These two 
piglets feeders were separated approximately 100 meters to avoid 
monopolization by any dominant family group. They were placed nearby a 
permanent waterhole (to ensure passing by) in a spot where they received 
afternoon shadow (to avoid thermic pressure over vaccines). Managed sites 
(BCG and IV) had 10 couples of piglet feeders each and natural sites 14 couples 
each (total piglet feeders =96). A detailed map of piglet-feeder distribution is 
provided in Supplementary Material 1. 
 
Vaccination schedule 
Vaccination took place in summer to target the main peak of 2-6 month old wild boar 
once they are into solid food consumption and to take advantage of the limited natural 
food resources available in Mediterranean habitats in this season. Maize was pre-baited 
2-5 times a week for 8 weeks prior to vaccine deployment and sham baits (without 
vaccine or marker) were placed as well to habituate wild boar piglets to baits. Pre-
baiting helps getting wild boar used to visit piglet feeders and limits uptake by non-
target species (Kaden et al. 2000, Ballesteros et al. 2011).  
The vaccination campaign included 3 cycles that consisted of three nights each. Two 
cycles were held consecutively on early summer (end of June-July) and one in late 
summer (end of August-September). 
Twenty baits per piglet feeder were deployed each day at dusk leading to a total of 
17.280 vaccine baits per year (180 baits/km2 and year). Non-consumed baits were 
retrieved the next morning and fresh vaccine baits were newly placed each day 
(maximum exposure to environmental temperatures was 12 hours). 
 
Vaccine impact assessment 
Hunter-harvested wild boar (n=1140) were sampled during the regular hunting season 
(October to February) from 2011-12 to 2015-16. Samples obtained prior to vaccination 
(hunting season 2011-12, from now on control year) serve as pre-intervention 
background providing baseline data on infection and disease. A representative sample 
stratified by age and sex of the hunted animals was randomly selected at each hunting 
event. Each specimen was subjected to collection of biometrical data, sex and age 
determination, blood collection from the cavernous sinus (Arenas-Montes et al. 2013) 
and a general inspection of the whole carcass. Age was assessed based on tooth eruption 
patterns (Saenz de Buruaga et al. 1991), establishing three categories: wild boar less 
than 12 months old were classified as piglets (n= 245), those between 12 and 24 months 
as yearlings (n= 305), and those over 2 years as adults (n= 590).  
Organ samples taken in the field include the mandibular lymph nodes (LNs), tonsils, the 
lung with the tracheobronchial LNs and mediastinal LN, the spleen, and the mesenteric 
LNs (Martín-Hernando et al. 2007). Detailed inspection by serial sectioning in the 
laboratory allowed recording TBCL presence and lesion scoring. A simple lesion 
scoring method was developed to inform on lesion severity (Díez-Delgado et al. 2014).  
Briefly, the lesion score is based on lesion size (0 if no lesion is present, 1 for lesions <1 
cm and 2 for larger sized lesions) and inspection of the routine target organs 
(considering each lung lobe separately and excluding the tonsil). Hence, the total lesion 
score of an individual ranges from 0 to 26. Individuals with lesion score >0 are defined 
as TBCL positive. Processed tissues were stored at -20ºC. Mandibular LN and tonsil 
pool plus a thoracic LN pool were cultured following the procedures described in 
Garrido et al. (2011). All isolates were spoligotyped (Kamerbeek et al. 1997). Wild boar 
with mycobacterial growth confirmed by spoligotyping as M. bovis or M.caprae were 
defined as culture positive. 
 
Bait uptake assessment  
Bait uptake is determined by the presence of chemical marker in serum. The IPA 
derivatives analysis was done following the extraction method and LC/ESI-MS analysis 
described in Ballesteros et al. (2010). The detection time of marker in serum after bait 
ingestion lasts for up to 18 months (Ballesteros et al. 2010). Thus, marker presence is 
used to estimate bait uptake in the vaccination campaign previous to the hunting season 
by individual wild boar (discriminating if older wild boar consumed bait as piglets is 
not possible).  
 
Statistics 
Descriptive analysis, predictors, and logistic regression 
Changes in temporal trends were analysed by means of a Chi square test or Fisher exact 
test (two tailed) when required. Data on study area rainfall was obtained from National 
Agency of Meteorology, Station 4184. The cumulative annual rainfall was calculated 
from September to August to match sampling years rather than natural years. 
For wild boar population monitoring, relative wild boar abundance estimates based on a 
dropping frequency index (FBII; Acevedo et al., 2007) were obtained yearly for the 
vaccinated sites (n=4) and the majority of control sites (n=11). 
In order to assess vaccine impact (defined as the combined probability of bait uptake 
and protection) for each site as compared to control sites while controlling for known 
disease drivers, a logistic regression model was fit using lesion presence as dependent 
variable.  
Independent variables introduced in the model where known drivers of TB (Vicente et 
al. 2013): age, rainfall (cm), relative wild boar abundance (FBII), years (1 to 4); and 
initial TB prevalence (proportion) to account for the situation prior to intervention. All 
analyses and data visualization were undertaken in the R statistical package (R 
Development Core Team, 2015) using the packages: ggplot 2 (Wickham 2009), 
reshape2 (Wickham 2007). Significance was fixed at p < 0.05. The 95% confidence 
intervals (CI) were calculated by bootstrapping. 
 
Modelling 
To answer questions that could not be tested in this field trial and gain insight into the 
mechanisms that govern the dynamics of vaccinating against TB in wild boar, a 
mathematical model representing the key processes in this system was developed. The 
model reflects a single geographical estate containing a homogeneously mixed 
population with parameters that are representative of the field trial sites. Two different 
scenarios representing our vaccination sites were modelled: (a) site with medium initial 
prevalence where piglets have a low chance of infection prior to vaccination (default 
disease transmission rate and no pseudo-vertical transmission); and (b) site with higher 
initial prevalence and greater rates of transmission combined with a greater proportion 
of piglets infected prior to vaccine delivery (double transmission rate and 100% pseudo-
vertical transmission). Three situations were addressed: (i) the influence of different 
levels of vaccination success (effective immunization) on disease prevalence, (ii) the 
influence of continued vaccination (25 years) and eventual cessation on population 
density, and (iii) on disease prevalence. The model framework, parameterization and 
interpretation are explained in Supplementary Material 2. 
 
 
RESULTS    
 
Bait uptake 
The proportion of individual wild boar with chemical marker presence in serum by site 
and age class is displayed in Figure 2. Piglets from Natural sites had lower uptake rates 
(50 to 74%) than those from managed sites (89 to 92%). The chemical marker was 
detected as well in older wild boar (42-59%).  
The topographical barrier separating different vaccine treatments in the Natural sites 
was not fully effective: consumption of both vaccine types (positive for both markers) 
was detected in 22-39% of vaccinated wild boar from the Natural sites. 
 
Vaccine impact 
Figure 3 presents the observed temporal trend of TBCL prevalence in piglets and at the 
population scale. The agreement between TBCL and culture had a kappa value of 0.68 
(raw data on TBCL, lesion score and culture are listed in Supplementary Material 3).  
Piglets showed a high initial infection pressure as the mean initial TBCL prevalence 
was 50% for the treatment sites and 53% for control sites. However, the initial piglet 
TBCL prevalence was highly variable and ranged from 0% to 100% among sites. At the 
end of the experiment, piglet TBCL prevalence had increased by 6% in both, the 
Control and Managed BCG sites, and decreased 36% in the Natural IV site. In the 
Natural BCG site the control year sample size was too low for comparisons. In the 
managed IV site, piglet TBCL prevalence remained 0% throughout the study period. 
At the population scale, the TBCL prevalence evolution during this five-year period 
increased steadily but not significantly in the Control sites (5.6% increase, X2 = 0.922, 1 
d.f., p >0.05). Regarding the treated sites, a significant decline occurred in the Managed 
IV site (34.4% reduction since control year; X2 = 7.665, 1 d.f., p <0.01). In this site, 
vaccination appeared to prevent infection and reduce disease severity (see 
Supplementary Material 3). No significant changes were recorded in the remaining sites 
(p>0.05). The inter-annual variability in TBCL prevalence was high, particularly in the 
Natural sites (Figure 3). 
Table 2 displays the results of the logistic regression model. Vaccination had a 
significant effect when IV was used in the Managed site (p <0.001). However, the effect 
of vaccination was negligible for the sites in which BCG was deployed (p>0.05) as well 
as for the Natural IV site (p >0.05). Other significant variables explaining TBCL 
presence in our model were increasing age, low rainfall and initial prevalence. 
 
Modelling 
Two scenarios representing our vaccination sites were investigated: (a) similar to 
Managed sites (medium initial prevalence where piglets have a low chance of infection 
prior to vaccination) ; and (b) similar to Natural sites (high initial prevalence and greater 
rates of transmission combined with a greater proportion of piglets infected prior to 
vaccine delivery). 
Effects of vaccination success on disease prevalence 
Figure 4 a(i) & b(i) shows that as the proportion of successfully vaccinated piglets 
(those that receive vaccine and are receptive to immunization thus resulting effectively 
immunized) increases, TB prevalence decreases (30% and 20% decrease, respectively, 
when vaccination success is 100%). This decrease in total prevalence is driven by less 
generalized infections and is greatest when piglets have a lower risk of infection prior to 
vaccination (a(i)). 
Effects of continued vaccination (25 years) and eventual cessation on population 
density and disease prevalence 
Figure 4 a(ii) & b(ii) shows the epidemiological dynamics regarding population density 
for a 25 year vaccination program when a 75% vaccine success level its assumed. It 
indicates that there is an initial reduction in the level of infected and generalized 
individuals, which lowers disease transmission and reduces mortality as less individuals 
progress to the generalized class in which disease induced mortality is substantial. The 
drop in the force of infection following vaccination drives an increase in total 
population density. Therefore, the reduction in disease prevalence shown in Figure 4 
(a(iii) & b(iii)) is a consequence of an increase in total population density rather than a 
decrease in the density of infected and generalized individuals.  
Population increase is driven by an increased pool of susceptibles which, in turn, can 
support a greater density of infected and generalized individuals. This explains why 
vaccination did not eradicate the disease in the model. The results for population density 
and disease prevalence on both scenarios are qualitatively similar but vaccine impact is 
less marked when pseudo-vertical and intense transmission take place.  
Moreover, model results highlight how observations from the early years of a 
vaccination program may not give a clear picture of the effectiveness of a long-term 
vaccination strategy, since in the initial stages the benefits of vaccination are not 
compensated by an increase in total population density.  
The model results also indicate that when the vaccination program is stopped there is an 
initial increase in disease prevalence and density of infected and generalized wild boar 
before levels return to those prior to vaccination. This is a consequence of the elevated 
population density resulting from vaccination and of the temporary nature of vaccine-




Our results confirmed the feasibility of bait deployment targeting wild boar piglets in 
Mediterranean habitats. Under optimal conditions of 90% piglet bait uptake and 
moderate (50%) initial infection prevalence, IV appeared to prevent infection and 
reduce disease severity, lowering TB prevalence at the population scale by 34% after 
four years. This result is particularly relevant in a context of increasing prevalence in 
the control sites. By contrast, no significant effects were found at a lower IV bait uptake 
rate (74%) and high natural challenge or in the sites in which BCG was deployed. 
 
A key aspect of vaccination is to target enough individuals. In free-ranging populations 
this goal is difficult to achieve and assess. Commonly, bait uptake by piglets is a 
limiting factor in oral vaccination via baits (Kaden et al. 2000) but this trial was able to 
reach more than 70% of this age class in three of four sites. This is relevant regarding 
the potential of vaccination for controlling other diseases, e.g. classical swine fever, in 
case of eventual emergence in Mediterranean regions. In this study, higher uptake was 
achieved in populations used to being fed and to human presence, i.e. managed hunting 
estates. Management, a risk factor for TB (Vicente et al. 2013), can thus be helpful in 
vaccine delivery while naïve populations might take longer to get used to new food 
sources (Delahay 2003). Nevertheless, in highly prevalent populations, aggregation at 
piglet feeders could offset vaccination benefits through increased transmission 
(Sorensen et al. 2014).  
Despite using piglet feeders, a proportion of older age individuals (42-59%)  gained 
access to baits. The effect of vaccination in adults is unknown. We speculate it could act 
as a protective revaccination prolonging immunity of the individuals (as long as they are 
uninfected) but it will decrease bait availability for piglets. 
 
The need of assessing new tools, such as vaccination, to manage TB effectively in wild 
boar is evident from the baseline situation of Mediterranean populations. In this region, 
monitoring has shown a 13% increase in wild boar TB between 2000 and 2012 (Vicente 
et al. 2013). In the control sites, wild boar TB prevalence was already high prior to 
intervention (mean 63% in 2012) and grew 5.6% during the five-year study period.  
 
The impact of BCG deployment was not significant, as prevalence remained stable. 
BCG is known to confer variable protection in humans and cattle (Fine et al. 1995, 
Buddle et al. 2013) and field trials where BCG failed to confer any protection have been 
reported (e.g. Baily et al. 1980 and Beggren 1981). Field trials deploying BCG in other 
wildlife hosts demonstrated protective effect over vaccinated individuals but effects at 
the population level were less evident (Table 1). While we can ensure BCG viability 
through the study (Beltrán-Beck et al. 2014b), we cannot rule out interference due to 
non-tuberculous mycobacteria priming, genetic differences, nutritional status, co-
infections etc. (Fine et al. 1995 and Buddle et al. 2013). 
 
Regarding IV, a significant 34% reduction in TBCL prevalence was observed in one of 
the sites but vaccine impact was negligible in the other. This suggests that the effect of 
vaccination is context dependent. Vaccine performance can be affected by initial 
prevalence, pre-existing infection, population and disease dynamics (Gormley et al. 
2011) and vary over time (Halloran et al. 1997) or in space (Kaden et al. 2000). 
Potential explanations for the different vaccine impact in these two settings are: 
heterogeneous exposure to MTC, different vaccination success achieved and inter-
population mixing.  
Regarding the first explanation, exposure heterogeneity (in terms of infective dose and 
number of reinfections), would to some extent explain the results obtained as vaccines 
are believed to protect better against a light challenge (Clemens et al. 2011). Since 
experimental challenge is thought to be more severe than the one occurring under 
natural circumstances, it has been proposed that vaccine efficacy will be greater under 
field conditions. Studies in Table 1 were conducted in settings where the initial TB 
prevalence ranged from 5 to 35%. In our study, the Managed IV site was characterized 
by a moderate initial prevalence (50%), no generalization (lesions restricted to 
mandibular LNs) and low infection pressure for piglets, whereas the Natural IV site was 
characterized by high initial prevalence (77%), high proportion of generalized 
individuals (36%) and high proportion of diseased piglets (86%). Although in field 
trials the challenge dose is unknown, in the latter setting challenge might have been 
intense enough to resemble the one in laboratory trials where all individuals develop 
disease despite getting the vaccine.  The results obtained by modeling are along these 
lines and suggest that increased transmission intensity and proportion of already 
infected piglets reduces the impact attainable through vaccination (Figure 4).  
The bait uptake achieved (second explanation) in both IV sites was not significantly 
different (92 and 74%) but the proportion of successfully vaccinated individuals (those 
that receive vaccine and are receptive to immunization), might have been. The existence 
of already infected piglets by the time of vaccination (in which despite vaccine 
consumption no protection is expected) and the consumption of both vaccines (with 
possible non-protective outcomes; Diez-Delgado et al. 2014) can decrease the 
proportion of effectively immunized individuals. 
Third, permeable fences in Natural IV allow inter-population mixing (immigration/ 
emigration). These movements complicate the assessment of vaccine efficacy (dilution 
effect) and may act as a source of infection. Thus, we expect that closed and well-
delimited (wild boar proof fenced) populations will benefit most from vaccination. 
  
Predictive modeling suggests that vaccination is useful to control TB in wild boar but 
not enough to achieve eradication as a stand-alone tool. Moreover, we are considering 
the wild boar system in isolation, which is not realistic in Mediterranean settings, where 
several other wild and domestic hosts are likely contributing to MTC maintenance. Such 
complex settings would benefit from an integrated control scheme combining several 
tools, including wild boar vaccination, and targeting several hosts. 
The impact generated at population scale by vaccination reaches its maximum ca. 5 
years after starting the campaign. This is roughly the timeframe of this field experiment. 
During the vaccination campaign, a considerable pool of susceptibles builds up so once 
vaccination ceases; disease prevalence is expected to recover quickly. At the same time, 
the increase in susceptibles drives an increment of the overall population density. This 
implies that increased hunting or increased population control is required in order to 
balance the consequences of vaccination on population dynamics.  
 
CONCLUSIONS 
Our efforts to mimic a realistic bait deployment in free-ranging wild boar populations 
provide practical insights into the logistics of oral vaccination in Mediterranean 
ecosystems. Oral IV can contribute to TB control in its main Iberian reservoir, the wild 
boar. However, this study showed that IV performance is context dependent. This 
implies that successful vaccination will depend on tailored field protocols. We suggest 
that IV deployment should be regarded as just one tool among several others, and that 




We want to thank all landowners and rangers that allowed us to work in their properties 
and helped along these five years. Vaccination sites and their working teams deserve 
special acknowledgement: Quintos de Mora (OAPN; Mª Carmen López, Ángel Moreno 
and Jose Polo) and DHC/VLL (Alejandro Arasanz, Enrique Corredor, Rafa Corredor 
and Carlos Romero). I´d like to acknowledge as well the assistance provided by many 
volunteers and colleagues in the long fieldwork days (Jose Angel Armenteros, Azlan 
Che´Amat, Amanda García, Eduardo Laguna, Pablo Palencia and Alberto Yepes) and 
the useful insight and comments of Pelayo Acevedo. 
Funding 
This is a contribution to EU FP7 grant 613779 WildTBVac, to Plan Nacional I+D+i 
AGL2014-56305 from MINECO and to EU FEDER. IDD was supported by a 
predoctoral grant from MINECO.  
 
References 
1. Acevedo, P., J. Vicente, U. Hofle, J. Cassinello, F. Ruiz-Fons and C. Gortazar, 
2007: Estimation of European wild boar relative abundance and aggregation: a 
novel method in epidemiological risk assessment. Epidemiol. Infect., 135, 519-
527.  
2. Anderson, L. G., C. Gortázar, J. Vicente, M. R. Hutchings and P. C. L. White, 
2013: Modelling the effectiveness of vaccination in controlling bovine 
tuberculosis in wild boar. Wildlife Research, 40, 367-376. 
3. Aranaz, A., L. de Juan, N. Montero, C. Sanchez, M. Galka, C. Delso, J. Alvarez, 
B. Romero, J. Bezos, A. I. Vela, et al., 2004: Bovine tuberculosis 
(Mycobacterium bovis) in wildlife in Spain. Journal of Clinical Microbiology, 
42, 2602-2608.  
4. Arenas-Montes, A., I. García-Bocanegra, J. Paniagua, J. Franco, F. Miró, M. 
Fernández-Morente, A. Carbonero and A. Arenas, 2013: Blood sampling by 
puncture in the cavernous sinus from hunted wild boar. European Journal of 
Wildlife Research, 1-5. 
5. Baily, G. V. J., R. Narain and S. Mayurnath, 1980: Tuberculosis Prevention 
Trial, Madras. Indian j. med. res., 72. 
6. Ballesteros, C., J. M. Garrido, J. Vicente, B. Romero, R. C. Galindo, E. 
Minguijón, M. Villar, M. P. Martín-Hernando, I. Sevilla, et al., 2009a: First data 
on Eurasian wild boar response to oral immunization with BCG and challenge 
with a Mycobacterium bovis field strain. Vaccine, 27, 6662-6668. 
7. Ballesteros, C., R. Carrasco-García, J. Vicente, J. Carrasco, A. Lasagna, J. de la 
Fuente and C. Gortazar, 2009b: Selective piglet feeders improve age-related bait 
specificity and uptake rate in overabundant Eurasian wild boar populations. 
Wildlife Research, 36, 203-212. 
8. Ballesteros, C., C. Gortázar, M. Canales, J. Vicente, A. Lasagna, J. A. Gamarra, 
R. Carrasco-García and J. de la Fuente, 2009c: Evaluation of baits for oral 
vaccination of European wild boar piglets. Research in Veterinary Science, 86, 
388-393. 
9. Ballesteros, C., P. R. Camarero, C. Cristòfol, J. Vicente, C. Gortazar, J. de la 
Fuente and R. Mateo, 2010: Analysis by LC/ESI-MS of iophenoxic acid 
derivatives and evaluation as markers of oral baits to deliver pharmaceuticals to 
wildlife. Journal of Chromatography B: Analytical Technologies in the 
Biomedical and Life Sciences, 878, 1997-2002. 
10. Ballesteros, C., J. Vicente, R. Carrasco-García, R. Mateo, J. de la Fuente and C. 
Gortázar, 2011: Specificity and success of oral-bait delivery to Eurasian wild 
boar in Mediterranean woodland habitats. European Journal of Wildlife 
Research, 57, 749-757. 
11. Barasona, J. A., K. C. VerCauteren, N. Saklou, C. Gortazar and J. Vicente, 
2013: Effectiveness of cattle operated bump gates and exclusion fences in 
preventing ungulate multi-host sanitary interaction. Preventive Veterinary 
Medicine, 111, 42-50. 
12. Barasona, J. A., P. Acevedo , I. Díez-Delgado, J. Queiros, R. Carrasco-García, 
C. Gortázar and J. Vicente, 2016: Tuberculosis-associated death among adult 
wild boars, Spain, 2009–2014. Emerging Infectious Disease journal, 22, 2178. 
13. Berggren, S.A. ,1981: Field experiment with BCG vaccine in Malawi. British 
Veterinary Journal, 137, 88-94. 
14. Beltrán-Beck, B., J. De La Fuente, J. M. Garrido, A. Aranaz, I. Sevilla, M. 
Villar, M. Boadella, R. C. Galindo, J. M. Pérez De La Lastra, J. A. Moreno-Cid, 
et al., 2014a: Oral vaccination with heat inactivated Mycobacterium bovis 
activates the complement system to protect against tuberculosis. PLoS ONE, 9. 
15. Beltrán-Beck, B., B. Romero, I. A. Sevilla, J. A. Barasona, J. M. Garrido, D. 
González-Barrio, I. Díez-Delgado, E. Minguijón, C. Casal, J. Vicente, et al., 
2014b: Assessment of an oral Mycobacterium bovis BCG vaccine and an 
inactivated M. bovis preparation for wild boar in terms of adverse reactions, 
vaccine strain survival, and uptake by nontarget species. Clinical and Vaccine 
Immunology, 21, 12-20. 
16. Boadella, M., J. Vicente, F. Ruiz-Fons, J. de la Fuente and C. Gortazar, 2012: 
Effects of culling Eurasian wild boar on the prevalence of Mycobacterium bovis 
and Aujeszky's disease virus. Preventive Veterinary Medicine, 107, 214-221. 
17. Buddle, B. M., F. E. Aldwell, D. L. Keen, N. A. Parlane, K. L. Hamel and G. W. 
De Lisle, 2006: Oral vaccination of brushtail possums with BCG: Investigation 
into factors that may influence vaccine efficacy and determination of duration of 
protection. New Zealand Veterinary Journal, 54, 224-230. 
18. Buddle, B. M., N. A. Parlane, D. N. Wedlock and A. Heiser, 2013: Overview of 
vaccination trials for control of tuberculosis in cattle, wildlife and humans. 
Transboundary and Emerging Diseases, 60, 136-146. 
19. Chambers, M. A., F. Rogers, R. J. Delahay, S. Lesellier, R. Ashford, D. Dalley, 
S. Gowtage, D. Davé, S. Palmer, J. Brewer, et al., 2011: Bacillus Calmette-
Guérin vaccination reduces the severity and progression of tuberculosis in 
badgers. Proceedings of the Royal Society B-Biological Sciences, 278, 1913-
1920  
20. Clemens, J., S. Shin and M. Ali, 2011: New approaches to the assessment of 
vaccine herd protection in clinical trials. Lancet Infect. Dis., 11, 482-487. 
21. Corner, L. A. L., S. Norton, B. M. Buddle and R. S. Morris, 2002: The efficacy 
of bacille Calmette-Guérin vaccine in wild brushtail possums (Trichosurus 
vulpecula). Research in Veterinary Science, 73, 145-152. 
22. Cowie, C. E., M. R. Hutchings, J. A. Barasona, C. Gortázar, J. Vicente and P. C. 
L. White, 2016: Interactions between four species in a complex wildlife: 
livestock disease community: implications for Mycobacterium bovis 
maintenance and transmission. European Journal of Wildlife Research, 62, 51-
64. 
23. Cross, M. L., B. M. Buddle and F. E. Aldwell, 2007: The potential of oral 
vaccines for disease control in wildlife species. Veterinary Journal, 174, 472-
480. 
24. Delahay, R. J., G. J. Wilson, G. C. Smith and C. L. Cheeseman, 2003: 
Vaccinating badgers (Meles meles) against Mycobacterium bovis: The 
ecological considerations. Veterinary Journal, 166, 43-51.  
25. Díez-Delgado, I., M. Boadella, M. Martín-Hernando, J. A. Barasona, B. Beltrán-
Beck, D. González-Barrio, M. Sibila, J. Vicente, J. M. Garrido, J. Segalés et al., 
2014: Complex links between natural tuberculosis and porcine circovirus type 2 
infection in wild boar. BioMed Res. Int., 2014.  
26. Díez-Delgado, I., M. Villar, B. Romero, I.A. Sevilla, M.G. Geijo, J. de la 
Fuente, A. Aranaz, C. Gortázar, R.A. Juste, J.M. Garrido, 2014: Sensitization 
sequence is critical for protection in Mycobacterium bovis infection in wild boar. 
VI International M.bovis conference, Cardiff, Wales. 
27. Díez-Delgado, I., O. Rodríguez, M. Boadella, J. M. Garrido, I. A. Sevilla, J. 
Bezos, R. Juste, L. Domínguez and C. Gortázar, 2016: Parenteral vaccination 
with heat-inactivated Mycobacterium bovis reduces the prevalence of 
tuberculosis-compatible lesions in farmed wild boar. Transboundary and 
Emerging Diseases, n/a-n/a. 
28. Fine, P. E. M., 1995: Variation in protection by BCG: implications of and for 
heterologous immunity. The Lancet, 346, 1339-1345. 
29. Freuling, C. M., K. Hampson, T. Selhorst, R. Schröder, F. X. Meslin, T. C. 
Mettenleiter and T. Müller, 2013: The elimination of fox rabies from Europe: 
determinants of success and lessons for the future. Philosophical Transactions 
of the Royal Society of London B: Biological Sciences, 368. 
30. Garrido, J. M., I. A. Sevilla, B. Beltrán-Beck, E. Minguijón, C. Ballesteros, R. 
C. Galindo, M. Boadella, K. P. Lyashchenko, B. Romero, M. V. Geijo, et al., 
2011: Protection against tuberculosis in Eurasian wild boar vaccinated with 
heat-inactivated Mycobacterium bovis. PLoS ONE, 6, e24905  
31. Gormley, E. and L. A. L. Corner, 2011: Control of tuberculosis in badgers by 
vaccination: Where next? Veterinary Journal, 189, 239-241. 
32. Gormley, E., D. Ní Bhuachalla, J. O’Keeffe, D. Murphy, F. E. Aldwell, T. 
Fitzsimons, P. Stanley, J. A. Tratalos, G. McGrath, N. Fogarty, et al., 2017: Oral 
vaccination of free-living badgers (Meles meles) with Bacille Calmette Guérin 
(BCG) vaccine confers protection against tuberculosis. PLOS ONE, 12, 
e0168851. 
33. Gortazar, C., B. Beltrán-Beck, J. M. Garrido, A. Aranaz, I. A. Sevilla, M. 
Boadella, K. P. Lyashchenko, R. C. Galindo, V. Montoro, L. Domínguez, et al., 
2014: Oral re-vaccination of Eurasian wild boar with Mycobacterium bovis 
BCG yields a strong protective response against challenge with a field strain. 
BMC Veterinary Research, 10. 
34. Gortázar, C., A. Che Amat and D. J. O'Brien, 2015: Open questions and recent 
advances in the control of a multi-host infectious disease: Animal tuberculosis. 
Mammal Review, 45, 160-175. 
35. Gortázar, C. and M. Boadella, 2014: Animal tuberculosis in Spain: a multihost 
system. 
36. Halloran, M. E., C. J. Struchiner and I. M. Longini Jr, 1997: Study designs for 
evaluating different efficacy and effectiveness aspects of vaccines. Am. J. 
Epidemiol., 146, 789-803. 
37. Hardstaff, J. L., G. Marion, M. R. Hutchings and P. C. L. White, 2014: 
Evaluating the tuberculosis hazard posed to cattle from wildlife across Europe. 
Research in Veterinary Science, 97, Supplement, S86-S93. 
38. Kaden, V., E. Lange, U. Fischer and G. Strebelow, 2000: Oral immunisation of 
wild boar against classical swine fever: Evaluation of the first field study in 
Germany. Veterinary Microbiology, 73, 239-252. 
39. Kamerbeek, J., L. Schouls, A. Kolk, M. vanAgterveld, D. vanSoolingen, S. 
Kuijper, A. Bunschoten, H. Molhuizen, R. Shaw, M. Goyal et al., 1997: 
Simultaneous detection and strain differentiation of Mycobacterium tuberculosis 
for diagnosis and epidemiology. Journal of Clinical Microbiology, 35, 907-914. 
40. Kukielka, E., J. A. Barasona, C. E. Cowie, J. A. Drewe, C. Gortazar, I. Cotarelo 
and J. Vicente, 2013: Spatial and temporal interactions between livestock and 
wildlife in South Central Spain assessed by camera traps. Preventive Veterinary 
Medicine, 112, 213-221. 
41. LaHue, N. P., J. V. Baños, P. Acevedo, C. Gortázar and B. Martínez-López, 
2016: Spatially explicit modeling of animal tuberculosis at the wildlife-livestock 
interface in Ciudad Real province, Spain. Preventive Veterinary Medicine, 128, 
101-111. 
42. Langer, A.J. and LoBue P.A, 2014: Public health significance of zoonotic 
tuberculosis caused by the Mycobacterium tuberculosis complex 
43. Lesellier, S., S. Palmer, D. J. Dalley, D. Davé, L. Johnson, R. G. Hewinson and 
M. A. Chambers, 2006: The safety and immunogenicity of Bacillus Calmette-
Guérin (BCG) vaccine in European badgers (Meles meles). Veterinary 
Immunology and Immunopathology, 112, 24-37 
44. López, G., M. López-Parra, G. Garrote, L. Fernández, T. del Rey-Wamba, R. 
Arenas-Rojas, M. García-Tardío, G. Ruiz, I. Zorrilla, M. Moral and M. A. 
Simón, 2014: Evaluating mortality rates and causalities in a critically 
endangered felid across its whole distribution range. European Journal of 
Wildlife Research, 60, 359-366. 
45. Martin-Hernando, M. P., U. Hofle, J. Vicente, F. Ruiz-Fons, D. Vidal, M. 
Barral, J. M. Garrido, J. de La Fuente and C. Gortazar, 2007: Lesions associated 
with Mycobacterium tuberculosis complex infection in the European wild boar. 
Tuberculosis, 87, 360-367. 
46. Massei, G., J. Kindberg, A. Licoppe, D. Gačić, N. Šprem, J. Kamler, E. Baubet, 
U. Hohmann, A. Monaco, J. Ozoliņš, et al., 2015: Wild boar populations up, 
numbers of hunters down? A review of trends and implications for Europe. Pest 
Management Science, 71, 492-500. 
47. McVey, S. and J. Shi, 2010: Vaccines in Veterinary Medicine: A Brief Review 
of History and Technology. Vet. Clin. North Am. Small Anim. Pract., 40, 381-
392. 
48. Naranjo, V., C. Gortazar, J. Vicente and J. de la Fuente, 2008: Evidence of the 
role of European wild boar as a reservoir of Mycobacterium tuberculosis 
complex. Veterinary microbiology, 127, 1-9. 
49. Nol, P., M. V. Palmer, W. R. Waters, F. E. Aldwell, B. M. Buddle, J. M. 
Triantis, L. M. Linke, G. E. Phillips, T. C. Thacker, J. C. Rhyan, et al., 2008: 
Efficacy of oral and parenteral routes of Mycobacterium bovis bacilli Calmette-
Guerin vaccination against experimental bovine tuberculosis in white-tailed deer 
(Odocoileus virginianus): A feasibility study. Journal of Wildlife Diseases, 44, 
247-259. 
50. Nugent, G., I. J. Yockney, E. J. Whitford, M. L. Cross, F. E. Aldwell and B. M. 
Buddle, 2016: Field trial of an aerially-distributed tuberculosis vaccine in a low-
density wildlife population of brushtail possums (Trichosurus vulpecula). PLOS 
ONE, 11, e0167144. 
51. Rappuoli, R., H. I. Miller and S. Falkow, 2002: Medicine: The intangible value 
of vaccination. Science, 297, 937-939. 
52.  R Development Core Team, 2015: R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 
Available at URL: https://www.R-project.org/. 
53. Reviriego Gordejo, F. J. and J. P. Vermeersch, 2006: Towards eradication of 
bovine tuberculosis in the European Union. Veterinary Microbiology, 112, 101-
109. 
54. Saenz de Buruaga, M., A. J. Lucio and F. J. Purroy, 1991: Reconocimiento de 
sexo y edad en especies cinegéticas, 1st edn. Ediciones Leonesas SA. 
55. Sorensen, A., F. M. van Beest and R. K. Brook, 2014: Impacts of wildlife 
baiting and supplemental feeding on infectious disease transmission risk: A 
synthesis of knowledge. Preventive Veterinary Medicine, 113, 356-363. 
56. Tompkins, D. M., D. S. L. Ramsey, M. L. Cross, F. E. Aldwell, G. W. De Lisle 
and B. M. Buddle, 2009: Oral vaccination reduces the incidence of tuberculosis 
in free-living brushtail possums. Proceedings of the Royal Society B-Biological 
Sciences, 276, 2987-2995. 
57. Vicente, J., J. A. Barasona, P. Acevedo, J. F. Ruiz-Fons, M. Boadella, I. Diez-
Delgado, B. Beltran-Beck, D. González-Barrio, J. Queirós, V. Montoro, et al., 
2013: Temporal trend of tuberculosis in wild ungulates from mediterranean 
Spain. Transboundary and Emerging Diseases, 60, 92-103. 
58. Wickham, H., 2007: Reshaping Data with the reshape Package. Journal of 
Statistical Software, 21(12), 1-20. URL http://www.jstatsoft.org/v21/i12/. 
59. Wickham, H., 2009:  ggplot2: Elegant Graphics for Data Analysis. Springer-
Verlag New York. 
60. Zinsstag, J., E. Schelling, F. Roth and R. Kazwala, 2006: Economics of bovine 
tuberculosis. In: C. O. Thoen, J. H. Steele and M. J. Gilsdorf (eds), 





Figure 1. Study area. Location of study area, Montes de Toledo, central Spain. Sites 
involved in the field trial. Three types of sites can be differentiated: control sites where 
no treatment is employed (light grey), sites vaccinated with BCG (blue) and sites 
vaccinated with heat-inactivated M.bovis vaccine (IV; yellow). 
 
Figure. 2. - Bait uptake. Proportion of wild boar individuals positive to chemical 
marker detection in serum by site and age class. Bars are the percentage of individuals 
positive to detection of chemical marker, light grey bar represent single chemical 
marker detection and dark grey presence of both markers. Error bars are bootstrap 95% 
confidence intervals (CI). Red dashed line stands for the minimum theoretical 70% 
uptake threshold to achieve an effective intervention (Anderson et al. 2013). 
 
Figure 3.- Temporal trend of TBCL prevalence by site of the total population  and 
the piglet age class. The solid line represents total population and the dashed line the 
piglet age class. In the treatment sites control trend for total population (solid line) and 
piglets (dashed line) appears in light grey to provide background information. Error bars 
are bootstrap 95% CI.  
 
Figure 4.- Results for the wild boar TB. (a) represents a site with medium disease 
prevalence in which piglets have a low chance of infection prior to vaccination (default 
disease transmission rate and no pseudo-vertical transmission) (b) represents a site with 
higher initial prevalence and greater rates of transmission combined with a greater 
proportion of piglets infected prior to vaccine delivery (double transmission rate and 
100% pseudo-vertical transmission). Row (i) shows disease prevalence against 
proportional vaccination success, vp, with results determined at the stable endemic 
steady state when the specified level of vaccination is included; (ii) shows changes in 
population density against time (years) for a vaccination level of 75%, (vp = 0.75); and 
(iii) shows changes in disease prevalence against time (years) for a vaccination level of 
75%, (vp = 0.75). In the figures N (blue) is the total population density; I (magenta) the 
total density of infected but not generalized; G (red) the total density of generalized; S 
(green) is the total density of susceptibles; and PV (cyan) is the total density of 
vaccinated piglets. Also, ptot (black) is the proportion of the total population infected 
with TB (ptot = (I+G)/N); pinf (magenta) is the prevalence of infected but not 
generalized (pinf = I/N); and pgen (red) is the prevalence of generalized infection (pgen 







Species Vaccine Vaccine assessment Reference 












Clinical signs, lesion 






Corner et al. 
2002 
Possum BCG 107 cfu Oral 
(trapping) 
Transition probability from 
susceptible to infected 
(estimated by modelling) 
 
95%* Tompkins et 
al. 2009 
Possum BCG 108 cfu Oral 
(baiting) 
 
Lesion presence and 
cultured tissues 
81% Nugent et al. 
2016 
Badger BCG 106 cfu Intramuscular 
(trapping) 
 









Badger BCG 108 cfu Oral 
(trapping) 
Stat Pack serology 








Table 2.- Results of the logistic regression model of TBCL presence. Estimates (B), 
estimate associated standard error (SE) and p-value. Reference values for the variables 
age and site are piglets and control respectively.  
 
Predictor B (SE) 
     











Rainfall  -1.574 (0.532) ** 
FBII  -0.391 (0.363)  














Initial prevalence  0.839 (0.401) * 
Year  -0.074 (0.078)  
 
a Only results of three vaccination years available 
*** p<0.001  **   p<0.01  *    p<0.05  
	
Supplementary Information for the TB Model 
 
1.- Using mathematical modelling to examine the dynamics of the wild boar TB   
vaccination system 
The model reflects a single geographical managed estate containing a homogeneously mixed 
population covering a 3x3 km2 area. The population density of wild boar is separated into 
different age classes to capture distinct disease and biological characteristics for piglets (aged 0-
1 year) P, yearlings (aged 1-2 years) Y, and adults (aged 2 years+) A. Further, the age-classes 
are split into susceptible, infected and generalised (super-shedder) classes (subscripts S, I, G, 
respectively) to reflect the disease status of the population. The population dynamics of the wild 
boar TB system are represented by the following set of non-linear differential equations (which 
is an extension of classical disease modelling frameworks (see Anderson and May 1979 [1]; 





















Figure S1: A schematic representation of the wild boar TB vaccination model represented 
by Equations 1. The model represents the density of piglets P, yearlings Y, and adults A with 
age-classes split into susceptible, infected and generalised (super-shedder) classes (subscripts S, 
I, G respectively). The class PV represents vaccinated piglets and B represents the density of 





























Here, N represents the total wild boar population. Susceptible and infected yearlings and adults 
give birth to susceptible piglets at rates bY and bA respectively. Generalised yearlings and adults 
give birth to piglets at rate bG with a proportion pvt assumed infected (through pseudo-vertical 
transmission from sow to offspring) and the remainder, (1 - pvt), assumed susceptible. In this 
study we assume that bY = bA = bG. The total population is regulated through a crowding 
parameter, q, that acts to stabilise the total population to a carrying capacity, N = K, in the 
absence of disease. Maturity from piglets to yearlings and yearlings to adults occurs at rate m 
and piglets, yearlings and adults may die of natural causes at rates dP , dY , dA respectively. 
Here we assume dP = dY = dA. 
 
The prime driver for infection in the wild boar TB system is through environmental contact with 
free-living TB particles, with density B. We assume that free-living particles are shed from 
generalised wild boar at rate λ and decay at rate µ. Susceptible may become infected through 
contact with free-living TB particles with transmission coefficients ßP , ßY and ßA and infected 
can progress to the generalised class at rates εP , εY and εA for the different age classes 
respectively. We assume that individuals in the generalised class suffer additional disease 
induced mortality at rate α. We assume piglets and yearlings are more susceptible to TB 
infection than adults and so set ßP = ßY , which we assume to be three times greater than 
transmission for yearlings to be the same, ßP = ßY , and three times the rate for adults, ßA = 3ßY . 
Similarly we set the rate of progression to generalised infection for piglets and yearlings to be 
the same, εP = εY, and three times the rate for adults, εA = 1/3 εY .In this way we have set the 
model so that the yearling class is the same as the piglet class in terms of disease characteristics, 
but the yearling class is the same as the adult class in terms of reproductive processes. 
 
We represent vaccination in the model by assuming a proportion, vP, of susceptible births enter 
the immune piglet class PV. The vaccinated piglets lose their immunity at rate mV maturing into 
the susceptible adult class. This implicitly assumes that when immunity is lost individuals have 
reached maturity and are able to reproduce but also have a reduced susceptibility to infection. 
Note, our vaccination coefficient combines the effects of both coverage and efficacy by 
representing the proportion of successful vaccinations. In the model the vaccination process is 
represented as a continuous process whereas in the field vaccination is applied to piglets aged 2-
6 months. Therefore, there is a chance of infection prior to vaccination and we approximate this 
with the inclusion of pseudo-vertical transmission from generalised individuals. 
 
2.- TB vaccination model parameters 
We use empirical data to set the model parameters and where information is not available we set 
values to approximate the observed prevalence, representative of the wild boar TB system in 
Central Spain. The parameters are as follows: 
 
bY = bA = bG = log(4) The population birth rate in a disease-free population when resources are 
unlimited. This constant rate means that for each reproductive member of the population, 
3 piglets will be born, averaged over the population over a year. (This has been derived by 
assuming that there is a 50% sex ratio and that each female produces an average of 6 offspring 
per year when resources are not limited.) 
 
K = 500 The carrying capacity for the total population in the target area in the absence of 
disease. 
 
q = 1    1 _ dA(dP+m)(dY +m)  This parameter limits the total population to the carrying capacity K in 
         K               m(bAm+bY dA)  
 
the populated disease-free steady state, and is derived from steady-state analysis of the model 
without infection. 
 
m = 1 The rate that piglets mature to yearlings and yearlings mature to adults. These rates 
assume that it takes on average 1 year to enter the next age class. 
 
dP = dY = dA = 1/7  The natural death rate of all classes which implies an average life expectancy 
of 7 years. 
 
ßP = ßY = cßßA = 20/ K The infection rates are fitted to give prevalence levels observed in the wild 
boar TB system in central Spain. We assume that cß = 3 and so disease transmission to piglets 
and yearlings is three times that of the adult rate under the assumption that transmission is 
higher for piglets and yearlings than it is for adults. 
 
εP = εY = 2 The rate that infected piglets and yearlings become generalised. This assumes that it 
takes on average 6 months for an infected piglet or yearling to progress to the generalized class. 
 
εA = 2/3 This is the rate that infectious adults become generalised. This assumes that it takes on 
average 18 months for an infected adult to progress to the generalised class. 
 
α = 1 This is the additional disease induced death rate of the generalised class and assumes that 
on average individuals spend 1 year in the generalised class before death. 
 
λ = 1 The rate of shedding of infectious particles by generalised classes. We normalise this 
value to 1. This is valid as we have explored a range of values for ßP, ßY and ßA which scale with 
the size of λ and the density of free-particles, B. 
 
µ= 6 This is the decay rate for free-living particles, indicating that they have an average life 
expectancy of 2 months. 
 
pvt The proportion of generalised births that result in pseudo-vertical transmission. In this study 
we assume pvt = 0 or 1. 
 
vP The proportion of susceptible births successfully vaccinated. We explore the full range of 
possible values of vP in this study. 
 
mV = 1 The rate that vaccinated piglets mature into the susceptible adult class. This assumes that 
when immunity is lost individuals are able to reproduce but also have the same reduced 
susceptibility to infection as adults. 
 
3.- TB vaccination model results 
In the results that follow we will refer to the total density of susceptibles as S where S = 
PS+YS+AS; the total density of infected but not generalised as I where I = PI + YI + AI ; and the 
total density of generalised as G where G = PG + YG + AG. The total population density, N, can 
therefore be defined as N = S+PV +I +G, which is at steady state, N = PS +YS +AS = K, in the 
absence of disease. All the densities are expressed in terms of population per geographical area. 
We define the total prevalence, ptot = (I+G)/N , as the proportion of the total population infected 
with TB; the prevalence of infected but not generalised pinf = I/N ; and the prevalence of 
generalised pgen = G/N ; such that ptot = pinf + pgen. We used MATLAB to obtain numerical results 
for the model as the proportion of successfully vaccinated piglets vP is varied. We use the 
default parameter set detailed in Section 2 under conditions of 0 or 100% pseudo-vertical 
transmission, pvt = 0 or 1. We consider results for both the default transmission coefficient, 
which results in a medium disease prevalence at steady state, and twice the default transmission 
value to reflect a greater risk of TB infection resulting in higher disease prevalence at the 
endemic steady state. We run the model until it has reached a stable endemic steady state then 
include vaccination for a period of 25 years to achieve a stable vaccinated steady state. We 
examine how vaccination affects the disease prevalence statistics ptot, pinf and pgen and the 
epidemiological dynamics. 
 
We examine results for the model described by Equations 1a-1k in different combinations of 
disease transmissions rates and pseudo-vertical transmission.  
Figure S2 (a) shows results for the default parameter set from Section 2 and 0% pseudo-vertical 
transmission; Figure S2 (b) shows results for default parameters with 100% pseudo-vertical 
transmission; Figure S2 (c) shows results for twice the default rate of disease transmission and 
0% pseudo-vertical transmission; and Figure S2 (d) shows results for twice the default rate of 
disease transmission with 100% pseudo-vertical transmission. Note, Figure S2 (a) and (d) also 
appear in the main text, denoted as Figure 4.- (a) & (b) respectively. 
Figure S2 (i) shows the change in disease prevalence for different levels of vaccination success 
(see also Table S1). Figures S2 (ii) and S2 (iii) show the epidemiological dynamics and changes 
in disease prevalence over time when we assume a 75% level of vaccination success.  
 
 
Table S1: Table showing changes in ptot, pinf and pgen for different levels of vaccination when 





Figure S2: Using default parameter values described in Section 2 with (a) 0% pseudo-vertical 
transmission; (b) 100% pseudo-vertical transmission; (c) 0% pseudo-vertical transmission with 
disease transmission twice the default value; and (d) 100% pseudo-vertical transmission with 
disease transmission twice the default value. Row (i) shows disease prevalence against 
proportional vaccination success, vp, with results determined at the stable endemic steady state 
when the specified level of vaccination is included; (ii) shows changes in population density 
against for a vaccination level of 75%, (vp = 0:75); and (iii) shows changes in disease 
prevalence against for a vaccination level of 75%, (vp = 0:75). Here ptot (black) is the 
proportion of the total population infected with TB; pinf (magenta) the prevalence of infected 
but not generalised; pgen (red) the prevalence of generalised; N(blue) is the total population 
density, I(magenta) the total density of infected but not generalised; G(red) the total density of 
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Vaccinated BCG 19 Private 
hunting site 
0.4 Yes 





Control None 30 Comunal land 0.1 No No 36 
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Control None 14 Private 
hunting site 
0.5 Yes 
(wild boar proof) 
 
Yes 92  
8 
 
Control None 22 Private 
hunting site 
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(wild boar proof) 
 
Yes 82 
9 Control None 8 Private 
hunting site 
 
n.a. No No 64 
10 
 
Control None 22 Comunal land 0.1 No No 40 
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Control None 9 Private 
hunting site 
1.2 Yes 





Control None 26 Private 
hunting site 
0.2 Yes 





Control None 20 Private 
hunting site 
0.4 Yes 





Control None 21 Comunal land 0.3 No No 33 
17 Control None 23 Private 
hunting site 
0.3 Yes 





Control None 19 Private 
hunting site 
0.3 Yes 
(wild boar proof) 
 
Yes 79 
19d Vaccinated IV 21 Private 
hunting site 
0.5 Yes 
(wild boar proof) 
Yes 50 
 




































Control year Vaccination year 1 Vaccination year 2 Vaccination year 3 Vaccination year 4 
n + Prevalence 
(95%CI) 
n + Prevalence 
(95%CI) 
n + Prevalence 
(95%CI) 
n + Prevalence 
(95%CI) 
n + Prevalence 
(95%CI) 
Control                
Total population 160 101 63.13 
(56.25-70) 
155 104 67.10 
(59.38-74.84) 
102 74 72.55 
(63.73-80.39) 
161 111 68.94 
(61.49-75.79) 
112 77 68.75 
(59.82-76.81) 
Piglets 34 18 52.94 
(34.94-70.59) 
36 18 50 
(33.33-66.66) 
16 14 87.5 
(68.75-100) 
31 16 51.61 
(35.48-67.74) 
22 13 59.10 
(40.90-77.27) 
Managed BCG                
Total population 17 9 52.94 
(29.41-76.47) 
13 7 53.85 
(30.58-84.62) 
   16 8 50 
(25.00-75.00) 
   
Piglets 7 1 14.29 
(0-42.86) 
5 3 60 
(20-100) 
   5 1 20 
(0-60) 
   
Managed IV                
Total population 24 12 50 
(29.71-70.83) 
27 12 44.44 
(25.93-62.96) 
19 6 31.58 
(10.52-52.63) 
   32 5 15.63 
(3.13-28.13) 
Piglets 1 0 0 
 
2 0 0 
(0-0) 
6 0 0 
(0-0) 
   4 0 0 
(0-0) 
Natural BCG                
Total population 11 11 100 
(100-100) 
35 33 94.29 
(85.71-100) 
14 9 64.29 
(35.71-85.71) 
33 23 69.70 
(51.51-84.85) 
26 25 96.15 
(88.46-100) 
Piglets 1 1 100 
 
   2 1 50 
(0-100) 
6 3 50 
(16.67-83.33) 
6 5 83.33 
(50-100) 
Natural IV                
Total population 22 17 77.27 
(59.09-95.45) 
24 21 87.50 
(74.89-100) 
41 25 60.98 
(46.34-75.61) 
49 44 89.80 
(81.63-97.96) 
47 35 74.47 
(61.70-87.23) 
Piglets 7 6 85.71 
(57.14-100) 
2 0 0 
(0-0) 
11 3 27.27 
(0-54.54) 
9 7 77.78 
(44.44-100) 








Control year Vaccination year 1 Vaccination year 2 Vaccination year 3 Vaccination year 4 
n + Prevalence 
(95%CI) 
n + Prevalence 
(95%CI) 
n + Prevalence 
(95%CI) 
n + Prevalence 
(95%CI) 
n + Prevalence 
(95%CI) 
Control                
Total population 43 25 58.14 
(44.19-72.09) 
84 30 35.71 
(26.19-45.24) 
46 26 56.52 
(41.30-69.57) 
152 130 85.53 
(79.61-90.79) 
110 56 50.90 
(40.91-60.02) 
Piglets 15 11 73.33 
(53.33-93.33) 
36 12 33.33 
(19.44-50.00) 
16 14 87.5 
(68.75-100) 
30 24 80 
(66.58-93.33) 
22 10 45.45 
(22.73-68.18) 
Managed BCG                
Total population 12 6 50 
() 
12 8 66.67 
(41.67-91.67) 
   16 13 81.25 
(62.50-100) 
   
Piglets 7 1 14.29 
(0-42.86) 
5 3 60 
(20-100) 
   5 3 60 
(20-100) 
   
Managed IV                
Total population 12 5 41.67 
() 
27 4 14.81 
(3.70-29.63) 
18 6 33.33 
(11.11-55.56) 
   32 5 15.63 
(3.13-28.13) 
Piglets 1 0 0 
 
2 0 0 
(0-0) 
6 0 0 
(0-0) 
   4 0 0 
(0-0) 
Natural BCG                
Total population 7 5 71.43 
(42.86-100) 
35 25 71.43 
(57.14-85.71) 
14 11 78.57 
(57.14-100) 
33 26 78.79 
(63.64-90.91) 
26 23 88.46 
(76.92-100) 
Piglets 1 0 0 
 
1 0 0 
 
2 1 50 
(0-100) 
6 4 66.67 
(33.33-100) 
6 5 83.33 
(50-100) 
Natural IV                
Total population 16 13 81.25 
(62.34-100) 
24 18 75 
(58.33-91.67) 
41 25 60.97 
(46.34-75.61) 
49 46 93.88 
(85.71-100) 
47 35 74.47 
(61.70-85.11) 
Piglets 4 4 100 
(100-100) 
2 0 0 
(0-0) 
11 2 18.18 
(0-45.45) 
9 7 77.78 
(55.56-100) 








Control year  Vaccination year 1  Vaccination year 2  Vaccination year 3  Vaccination year 4 
n +   (G) Mean  n +   (G) Mean  n + (G) Mean 
 
 n + (G) Mean 
 
 n + (G) Mean 
 
Control                    
Total population 
 




 155 104 (54) 4.30 
 
 102 74 (41) 4.59 
 
 161 111 (53) 4.27 
 
 112 77 (36) 4.71 
 




 36 18 (6) 3.53 
 
 16 14 (9) 6.50 
 
 31 16 (10) 5.32 
 
 22 13 (5) 3.23 
 
Managed BCG                    




 13 7 (7) 4.62 
 
     16 8 (1) 1.38 
 
    




 5 3 (3) 8.20 
 
     5 1(0) 0.80 
 
    
Managed IV                    




 27 12 (4) 2.30 
 
 19 6 (3) 1.79 
 
     32 5 (1) 0.56 
0 




 2 0 (0) 0 
 
 6 0 0 
 
     4 0 0 
 
Natural BCG                    




 35 33 (25) 6.43 
 
 14 9 (5) 7.29 
 
 33 23 (17) 6.73 
 
 26 25 (15) 7.15 
6 




     2 1(0) 2 
 
 6 3 (1) 2 
 
 6 5 (3) 7 
 
Natural IV                    




 24 21 (16) 5.67 
 
 41 25 (12) 3.68 
 
 49 44 (20) 6.27 
 
 47 35 (17) 4.43 
 




 2 0 (0) 0 
 
 11 3 (2) 2.27 
 
 9 7 (4) 7.89 
 
 8 4 (2) 4.75 
 
	
